Universal Health Services stock
UHSNYSEUniversal Health Services, Inc., HealthcareISIN US9139031002
73Score 73 out of 100, Strong
Price and trend
85 / 100
Price history
−12% in one yearThe chart shows daily closes over 20 years, adjusted for stock splits and without dividends. Click into the chart to set a price alert at that price.
Above the 200-day line: the price is 11% above it.
Since October 2026 the 50-day line has been above the 200-day line; the trend has turned up.
Normal: the price is neither overheated nor sold off (RSI 57).
The price is 19% below its 52-week high. Largest decline in 20 years: 56% (September 2019 to March 2020).
Chart figures for advanced users
- SMA 50$180.16
- Average price of the last 50 trading days, shows the short-term trend.
- SMA 200$176.54
- Average price of the last 200 trading days, shows the long-term trend.
- RSI (14)57
- Relative strength over the last 14 days on a scale from 0 to 100. Above 70 the price counts as overheated, below 30 as sharply fallen.
- MACDabove the signal line
- Compares a fast and a slow price average. Above its signal line momentum is rising, below it momentum is fading.
- Support$141.17
- The lowest closing price of the last twelve months.
- Resistance$244.18
- The highest closing price of the last twelve months.
Snapshot
Computed from the data by fixed rules, no AI
- Universal Health Services, Inc. belongs to the Medical (Care Facilities) industry (United States) and, with a market value of $11.57B, is number 9 of 56 companies in its industry on MEQIRI.
- In fiscal 2025 it reported revenue of $17.36B (up 9.7% year on year) and earnings of $1.49B (up 30.4%).
- For fiscal 2026, analysts expect on average revenue of $18.61B (up 7.2%) and adjusted earnings per share of $22.42 (up 3%).
Show more
- MEQIRI Score 73 out of 100 (Strong): rank 101 of 714 in Healthcare, median 53.
- The P/E is 8 (Medical (Care Facilities) median 19.4, own median of recent years 14.2).
- Our model puts fair value at $489.13, with the price 60% below it.
In plain words
The numbers on this page in plain words, written by an AI
Strengths
- Modestly valuedP/E 8, Medical (Care Facilities) median 19.4, own median 14.2.Valuation 91
- Share buybacksShare count down 25% since 2020.Capital allocation 79
- Below fair valuePrice 60% below the fair value of $489.13.Valuation 91
Weaknesses
None of our weakness checks flags anything. Crash risk is measured separately.
Its standout strengths are valuation and technical analysis.
Daily figure as of 12 Nov 2026
How the score is calculatedScore overview
Fundamentals are strong, with stable profits.
Score history
The full history of up to 20 years comes with MEQIRI Pro.
See plansCrash risk low
How well MEQIRI warnsOne of the 30% with the lowest crash risk among smaller stocks.
From 2016 to 2025, 14 in 100 such stocks fell 30% or more within a year, against a group average of 23 in 100.
What lowers it
- solid fundamentals
Valuation
Valuation signal
Significantly undervaluedIn our model the price counts as cheap below $376.26 and expensive above $698.76 (uncertainty medium, based on the price swings of the past year).
The two parts of the fair value come to $499.79 (cash-flow model) and $478.48 (industry comparison), and the gap between them shows how uncertain the estimate is. The price is below both.
Calculated with a cost of equity of 8.8%. At 9.8% the fair value would be $445.27, at 7.8% it would be $555.10.
Valuation metrics
Half from the cash-flow model, half from earnings times the industry P/E (19.4).
Calculate with your own assumptionsCompany performance
This shows several years of history with an automatic assessment.
Revenue
In the twelve months to 30 Sep 2026, revenue rose 8% on the twelve months before. Revenue has grown solidly since 2006, at about 8% per year.
Margins
- Gross margin
- Operating margin
- Net margin
In fiscal 2025: gross 90%, operating 11%, net 9%.
Debt & balance sheet
latest quarterThe balance sheet is solid, with moderate debt and comfortable interest coverage.
Earnings
- Next earnings
- 24 Feb 2027in 104 days
- Last reported
- 27 Oct 2026EPS reported $5.22 (expected $5.19)in line with expectations
Analyst estimates
Analysts have cut their 2027 earnings estimate by 3.7% since 15 Oct 2026. Falling estimates often precede bad news.
- Earnings per share
- $22.42−0.6%
- Revenue
- $18.61B+0.1%
- Earnings per share
- $23.04−3.7%
- Revenue
- $19.48B0.0%
MEQIRI has stored the estimates since 15 Oct 2026. Until 30 days are available, the card shows the change since that day. Mean estimate according to Financial Modeling Prep. No price target and no recommendation.
Company outlook lowered
Share price after the results: −0.4%UHS reiterates its July full-year guidance but now expects results toward the lower end of that range, and operational break even at one hospital is pushed back from late 2026 to the first half of 2027.
“Because these practices remain at varying stages of developing their patient bases within the community, we now expect the hospital to reach operational break even in the first half of 2027, compared with our prior expectations of the fourth quarter of 2026.”The outlook is not part of the score and not a recommendation to buy or sell.
From the earnings call on 28 Oct 2026 (fiscal Q3 2026), read by AI.
Insiders
Open-market purchases and sales by executives, board members and major holders
No open-market purchases or sales in the last 6 months.
Source: Form 4 filings with the US Securities and Exchange Commission. Grants, option exercises, gifts and tax withholdings are hidden. Not a recommendation to buy.
What happened at Universal Health Services
The key events of the last six months from our own data. A click takes you to the matching card.
Sector comparison
714 rated companies in Healthcare
- This company
- 73
- Sector median
- 53
Categories against the sector median
The median is the middle value: half of the companies in the sector lie above it, half below. Categories with too few comparable companies are left out.
Competitors in Medical (Care Facilities)
The next larger and next smaller companies by market value
- Rede D'Or São LuizRDOR3.SA $13.45B62
- Apollo Hospitals EnterpriseAPOLLOHOSP.NS $13.2B70
- Aier Eye Hospital Group300015.SZ $12.08B66
- Fresenius Medical Care AG & Co. KGaAFME.DE $11.78B59
- DaVitaDVA $11.54B67
- Ensign GroupENSG $10.86B66
- Max Healthcare InstituteMAXHEALTH.NS $9.64B53
- PACS GroupPACS $7.95B67
ETFs that hold Universal Health Services
Held by 29 ETFs on Xetra. Shown per index: the ETF with the largest weight.
| ETF | Weight | Cost | Fund size |
|---|---|---|---|
| iShares Ageing Population UCITS ETF2B77 | 0.65% | 0.40% | €807M |
| State Street SPDR MSCI USA Small Cap Value Weighted UCITS ETFZPRV | 0.32% | 0.30% | €944.34M |
| Xtrackers S&P 500 Equal Weight UCITS ETF 2C EUR HedgedXDEE | 0.22% | 0.30% | €14.88B |
Show 5 more
| Invesco Global Buyback Achievers UCITS ETFBBCK | 0.18% | 0.39% | €188.08M |
| Invesco S&P 500 QVM UCITS ETFQVMP | 0.17% | 0.35% | €50.82M |
| State Street SPDR S&P U.S. Health Care Select Sector UCITS ETF (Acc)ZPDH | 0.15% | 0.15% | €592.11M |
| iShares S&P 500 Health Care Sector UCITS ETFQDVG | 0.15% | 0.15% | €3.27B |
| iShares MSCI World Small Cap UCITS ETFIUSN | 0.10% | 0.35% | €8.19B |
Holdings as reported by the funds via FMP, excluding swap ETFs (their holdings are only collateral).
Data status and sources
- Score
- Daily value of 12 Nov 2026, recalculated nightly
- Price
- Closing price of 11 Nov 2026
- Latest annual report
- Fiscal year 2025, period end 31 Dec 2025
- Source
- Financial statements, ratios and prices from Financial Modeling Prep (FMP), based on the company's reports. MEQIRI calculates the score and fair value from them.
Mandatory disclosures for this rating
- ; time horizon around 12 months
- Rated Strong, published since 7 Nov 2026 (in the score history since 5 Nov 2026)
- Valuation signal Undervalued since 7 Nov 2026
- End-of-day prices, metrics cached for up to 24 hours
- Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
- Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
- Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.